RGNX
Price
$12.89
Change
+$0.68 (+5.57%)
Updated
Dec 3, 04:59 PM (EDT)
Capitalization
638.36M
89 days until earnings call
Intraday BUY SELL Signals
SLDB
Price
$5.18
Change
+$0.08 (+1.57%)
Updated
Dec 3, 04:59 PM (EDT)
Capitalization
405.91M
Intraday BUY SELL Signals
Interact to see
Advertisement

RGNX vs SLDB

Header iconRGNX vs SLDB Comparison
Open Charts RGNX vs SLDBBanner chart's image
REGENXBIO
Price$12.89
Change+$0.68 (+5.57%)
Volume$5.34K
Capitalization638.36M
Solid Biosciences
Price$5.18
Change+$0.08 (+1.57%)
Volume$11.1K
Capitalization405.91M
RGNX vs SLDB Comparison Chart in %
RGNX
Daily Signal:
Gain/Loss:
SLDB
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
RGNX vs. SLDB commentary
Dec 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RGNX is a Hold and SLDB is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 04, 2025
Stock price -- (RGNX: $12.21 vs. SLDB: $5.11)
Brand notoriety: RGNX and SLDB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: RGNX: 34% vs. SLDB: 35%
Market capitalization -- RGNX: $638.36M vs. SLDB: $405.91M
RGNX [@Biotechnology] is valued at $638.36M. SLDB’s [@Biotechnology] market capitalization is $405.91M. The market cap for tickers in the [@Biotechnology] industry ranges from $107.98B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

RGNX’s FA Score shows that 1 FA rating(s) are green whileSLDB’s FA Score has 2 green FA rating(s).

  • RGNX’s FA Score: 1 green, 4 red.
  • SLDB’s FA Score: 2 green, 3 red.
According to our system of comparison, SLDB is a better buy in the long-term than RGNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

RGNX’s TA Score shows that 4 TA indicator(s) are bullish while SLDB’s TA Score has 5 bullish TA indicator(s).

  • RGNX’s TA Score: 4 bullish, 5 bearish.
  • SLDB’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, SLDB is a better buy in the short-term than RGNX.

Price Growth

RGNX (@Biotechnology) experienced а -9.22% price change this week, while SLDB (@Biotechnology) price change was -0.78% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.32%. For the same industry, the average monthly price growth was +1.23%, and the average quarterly price growth was +54.93%.

Reported Earning Dates

RGNX is expected to report earnings on Mar 03, 2026.

Industries' Descriptions

@Biotechnology (+0.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RGNX($638M) has a higher market cap than SLDB($406M). RGNX YTD gains are higher at: 57.956 vs. SLDB (27.750). RGNX has higher annual earnings (EBITDA): -129.93M vs. SLDB (-152.11M). RGNX has more cash in the bank: 323M vs. SLDB (268M). SLDB has less debt than RGNX: SLDB (23.1M) vs RGNX (77.7M). RGNX has higher revenues than SLDB: RGNX (156M) vs SLDB (0).
RGNXSLDBRGNX / SLDB
Capitalization638M406M157%
EBITDA-129.93M-152.11M85%
Gain YTD57.95627.750209%
P/E RatioN/AN/A-
Revenue156M0-
Total Cash323M268M121%
Total Debt77.7M23.1M336%
FUNDAMENTALS RATINGS
RGNX vs SLDB: Fundamental Ratings
RGNX
SLDB
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
72
Overvalued
21
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
3946
P/E GROWTH RATING
1..100
183
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SLDB's Valuation (21) in the Biotechnology industry is somewhat better than the same rating for RGNX (72). This means that SLDB’s stock grew somewhat faster than RGNX’s over the last 12 months.

SLDB's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as RGNX (100). This means that SLDB’s stock grew similarly to RGNX’s over the last 12 months.

RGNX's SMR Rating (97) in the Biotechnology industry is in the same range as SLDB (98). This means that RGNX’s stock grew similarly to SLDB’s over the last 12 months.

RGNX's Price Growth Rating (39) in the Biotechnology industry is in the same range as SLDB (46). This means that RGNX’s stock grew similarly to SLDB’s over the last 12 months.

SLDB's P/E Growth Rating (3) in the Biotechnology industry is in the same range as RGNX (18). This means that SLDB’s stock grew similarly to RGNX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
RGNXSLDB
RSI
ODDS (%)
Bearish Trend 6 days ago
90%
Bullish Trend 6 days ago
84%
Stochastic
ODDS (%)
Bearish Trend 6 days ago
87%
Bearish Trend 6 days ago
87%
Momentum
ODDS (%)
Bullish Trend 6 days ago
78%
Bullish Trend 6 days ago
82%
MACD
ODDS (%)
Bullish Trend 6 days ago
75%
Bullish Trend 6 days ago
75%
TrendWeek
ODDS (%)
Bullish Trend 6 days ago
78%
Bullish Trend 6 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 6 days ago
76%
Bearish Trend 6 days ago
90%
Advances
ODDS (%)
Bullish Trend 9 days ago
77%
Bullish Trend 6 days ago
78%
Declines
ODDS (%)
Bearish Trend 14 days ago
84%
Bearish Trend 20 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 6 days ago
90%
Aroon
ODDS (%)
Bearish Trend 6 days ago
84%
Bearish Trend 6 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
RGNX
Daily Signal:
Gain/Loss:
SLDB
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ETAHX51.30N/A
N/A
Eventide Healthcare & Life Sciences A
LZISX10.44N/A
N/A
Lazard Global Small Cap Eq Instl
DCCAX30.57N/A
N/A
Nomura Small Cap Core A
MMGEX10.12N/A
N/A
MassMutual Small Cap Gr Eq A
SLPAX15.04N/A
N/A
SEI Small Cap A (SIIT)

RGNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RGNX has been loosely correlated with SYRE. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if RGNX jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGNX
1D Price
Change %
RGNX100%
-3.10%
SYRE - RGNX
58%
Loosely correlated
-0.91%
BEAM - RGNX
55%
Loosely correlated
-2.83%
DNLI - RGNX
55%
Loosely correlated
-1.71%
VYGR - RGNX
55%
Loosely correlated
-4.89%
RXRX - RGNX
54%
Loosely correlated
-0.69%
More

SLDB and

Correlation & Price change

A.I.dvisor indicates that over the last year, SLDB has been loosely correlated with EDIT. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if SLDB jumps, then EDIT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SLDB
1D Price
Change %
SLDB100%
-1.92%
EDIT - SLDB
48%
Loosely correlated
-3.65%
BEAM - SLDB
47%
Loosely correlated
-2.83%
DSGN - SLDB
47%
Loosely correlated
+0.11%
SYRE - SLDB
47%
Loosely correlated
-0.91%
RGNX - SLDB
45%
Loosely correlated
-3.10%
More